First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report

Smith M, Fawcett S, Sigalas E, Bell R, Devery S, Andrieska N and Winship I: Familial breast cancer: Double heterozygosity for BRCA1 and BRCA2 mutations with differing phenotypes. Fam Cancer. 7:119–124. 2008. View Article : Google Scholar : PubMed/NCBI

Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Béroud C and Lidereau R: French BRCA GGC Consortium: Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Nucleic Acids Res. 40:D992–D1002. 2012. View Article : Google Scholar : PubMed/NCBI

Oncogénétique en 2014 - Consultations, laboratoires et prise en charge - reference: APPDECONCOG15. Institut National Du Cancer. (In French).

Deng CX and Brodie SG: Roles of BRCA1 and its interacting proteins. BioEssays. 22:728–737. 2000. View Article : Google Scholar : PubMed/NCBI

Roy R, Chun J and Powell SN: BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer. 12:68–78. 2011. View Article : Google Scholar : PubMed/NCBI

Petrucelli N, Daly MB and Feldman GL: BRCA1 and BRCA2 hereditary breast and ovarian cancerGeneReviews(^®) [Internet]. Pagon RA, Adam MP, Ardinger HH, et al: University of Washington; Seattle, WA: 1993. 2016

Thull DL and Vogel VG: Recognition and management of hereditary breast cancer syndromes. Oncologist. 9:13–24. 2004. View Article : Google Scholar : PubMed/NCBI

Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga JY, Gupta V, Costa R, Srock S, De Ducla S, et al: Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): A randomised, open-label, phase 3 trial. Lancet Oncol. 15:1351–1360. 2014. View Article : Google Scholar : PubMed/NCBI

Leegte B, van der Hout AH, Deffenbaugh AM, Bakker MK, Mulder IM, ten Berge A, Leenders EP, Wesseling J, De Hullu J, Hoogerbrugge N, et al: Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations. J Med Genet. 42:e202005. View Article : Google Scholar : PubMed/NCBI

Choi DH, Lee MH and Haffty BG: Double heterozygotes for non-Caucasian families with mutations in BRCA-1 and BRCA-2 genes. Breast J. 12:216–220. 2006. View Article : Google Scholar : PubMed/NCBI

Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST and Eng CM: Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet. 63:45–51. 1998. View Article : Google Scholar : PubMed/NCBI

Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE and Begg CB: The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev. 10:467–473. 2001.PubMed/NCBI

Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J and Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 91:943–949. 1999. View Article : Google Scholar : PubMed/NCBI

Andersen TI, Børresen AL and Møller P: A common BRCA1 mutation in Norwegian breast and ovarian cancer families? Am J Hum Genet. 59:486–487. 1996.PubMed/NCBI

Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, Samson C, Leblanc JF, Bélanger C, Dion F, et al: Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet. 8:392–398. 1994. View Article : Google Scholar : PubMed/NCBI

Dørum A, Heimdal K, Hovig E, Inganäs M and Møller P: Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer. Am J Hum Genet. 65:671–679. 1999. View Article : Google Scholar : PubMed/NCBI

Novaković S, Milatović M, Cerkovnik P, Stegel V, Krajc M, Hočevar M, Zgajnar J and Vakselj A: Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families. Int J Oncol. 41:1619–1627. 2012.PubMed/NCBI

Tea M-KM, Kroiss R, Muhr D, Fuerhauser-Rappaport C, Oefner P, Wagner TM and Singer CF: Central European BRCA2 mutation carriers: Birth cohort status correlates with onset of breast cancer. Maturitas. 77:68–72. 2014. View Article : Google Scholar : PubMed/NCBI